Newbury Pharmaceuticals
3.14 SEK -2.48%1 investor is following this company
Newbury Pharmaceuticals is a pharmaceutical company. The company develops a pipeline of in-house developed and licensed products with a focus on specialty drugs in areas such as oncology, rare diseases, and neurology. The company conducts its business within the Scandinavian market. Newbury Pharmaceuticals was founded in 2020 and has its headquarters in Lund.
Revenue
10.27M
EBIT %
-190.75 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
NEWBRY
Daily low / high price
2.4 / 3.22
SEK
Market cap
76.17M SEK
Turnover
58.17K SEK
Volume
19K
Financial calendar
Interim report
2024-07-10
Annual report
2024-10-09
General meeting
2025-01-15
Interim report
2025-01-15
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Karl Karlsson | 41.1 % | 41.1 % |
Sumar Pharma | 12.7 % | 12.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Newbury Pharmaceuticals is strengthening its portfolio with Dalbavancin Powder
Redeye: Newbury Pharmaceuticals Q2 - A bump in the road
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools